Your browser doesn't support javascript.
loading
Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.
Zhao, Yongdong; Wu, Eveline Y; Oliver, Melissa S; Cooper, Ashley M; Basiaga, Matthew L; Vora, Sheetal S; Lee, Tzielan C; Fox, Emily; Amarilyo, Gil; Stern, Sara M; Dvergsten, Jeffrey A; Haines, Kathleen A; Rouster-Stevens, Kelly A; Onel, Karen B; Cherian, Julie; Hausmann, Jonathan S; Miettunen, Paivi; Cellucci, Tania; Nuruzzaman, Farzana; Taneja, Angela; Barron, Karyl S; Hollander, Matthew C; Lapidus, Sivia K; Li, Suzanne C; Ozen, Seza; Girschick, Hermann; Laxer, Ronald M; Dedeoglu, Fatma; Hedrich, Christian M; Ferguson, Polly J.
Afiliação
  • Zhao Y; Seattle Children's Hospital, University of Washington, Seattle.
  • Wu EY; University of North Carolina, Chapel Hill.
  • Oliver MS; Stanford Children's Health, Stanford University, Palo Alto, California.
  • Cooper AM; Children's Mercy, Kansas City, Missouri.
  • Basiaga ML; Seattle Children's Hospital, University of Washington, Seattle.
  • Vora SS; Levine Children's Hospital, Charlotte, North Carolina.
  • Lee TC; Stanford Children's Health, Stanford University, Palo Alto, California.
  • Fox E; Children's Mercy, Kansas City, Missouri.
  • Amarilyo G; Schneider Children's Medical Center of Israel, Petach Tikva Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Stern SM; University of Utah, Salt Lake City.
  • Dvergsten JA; Duke Children's Hospital, Durham, North Carolina.
  • Haines KA; Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey.
  • Rouster-Stevens KA; Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
  • Onel KB; Hospital for Special Surgery, New York, New York.
  • Cherian J; Stony Brook Children's Hospital, Stony Brook, New York.
  • Hausmann JS; Boston Children's Hospital and Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Miettunen P; University of Calgary, Calgary, Alberta, Canada.
  • Cellucci T; McMaster Children's Hospital, Hamilton, Ontario, Canada.
  • Nuruzzaman F; Stony Brook Children's Hospital, Stony Brook, New York.
  • Taneja A; Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
  • Barron KS; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Hollander MC; University of Vermont Medical Center, Burlington.
  • Lapidus SK; Goryeb Children's Hospital, Morristown, New Jersey.
  • Li SC; Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey.
  • Ozen S; Hacettepe University, Ankara, Turkey.
  • Girschick H; Vivantes Children's Hospital in Friedrichshain, Berlin, Germany.
  • Laxer RM; The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.
  • Dedeoglu F; Boston Children's Hospital, Boston, Massachusetts.
  • Hedrich CM; Children's Hospital Dresden, University Medical Center Carl Gustav Carus, TU Dresden, Dresden, Germany, and Institute of Translational Medicine, University of Liverpool, and Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK.
  • Ferguson PJ; University of Iowa Carver College of Medicine, Iowa City.
Arthritis Care Res (Hoboken) ; 70(8): 1228-1237, 2018 08.
Article em En | MEDLINE | ID: mdl-29112802
ABSTRACT

OBJECTIVE:

To develop standardized treatment regimens for chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO), to enable comparative effectiveness treatment studies.

METHODS:

Virtual and face-to-face discussions and meetings were held within the CNO/CRMO subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA). A literature search was conducted, and CARRA membership was surveyed to evaluate available treatment data and identify current treatment practices. Nominal group technique was used to achieve consensus on treatment plans for CNO refractory to nonsteroidal antiinflammatory drug (NSAID) monotherapy and/or with active spinal lesions.

RESULTS:

Three consensus treatment plans (CTPs) were developed for the first 12 months of therapy for CNO patients refractory to NSAID monotherapy and/or with active spinal lesions. The 3 CTPs are methotrexate or sulfasalazine, tumor necrosis factor inhibitors with optional methotrexate, and bisphosphonates. Short courses of glucocorticoids and continuation of NSAIDs are permitted for all regimens. Consensus was achieved on these CTPs among CARRA members. Consensus was also reached on subject eligibility criteria, initial evaluations that should be conducted prior to the initiation of CTPs, and data items to collect to assess treatment response.

CONCLUSION:

Three consensus treatment plans were developed for pediatric patients with CNO refractory to NSAIDs and/or with active spinal lesions. Use of these CTPs will provide additional information on efficacy and will generate meaningful data for comparative effectiveness research in CNO.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteomielite / Planejamento de Assistência ao Paciente / Doenças da Coluna Vertebral / Produtos Biológicos / Anti-Inflamatórios não Esteroides / Antirreumáticos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteomielite / Planejamento de Assistência ao Paciente / Doenças da Coluna Vertebral / Produtos Biológicos / Anti-Inflamatórios não Esteroides / Antirreumáticos Idioma: En Ano de publicação: 2018 Tipo de documento: Article